These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36289175)

  • 41. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.
    Paris A; Bora P; Parolo S; MacCannell D; Monine M; van der Munnik N; Tong X; Eraly S; Berger Z; Graham D; Ferguson T; Domenici E; Nestorov I; Marchetti L
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):196-206. PubMed ID: 36471456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
    Li Q
    Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen.
    Trifunov S; Natera-de Benito D; Carrera-García L; Codina A; Expósito-Escudero J; Ortez C; Medina J; Torres Alcala S; Bernal S; Alias L; Badosa C; Balsells S; Alcolea D; Nascimento A; Jimenez-Mallebrera C
    J Neuromuscul Dis; 2023; 10(4):653-665. PubMed ID: 37038823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy.
    Errico F; Marino C; Grimaldi M; Nuzzo T; Bassareo V; Valsecchi V; Panicucci C; Di Schiavi E; Mazza T; Bruno C; D'Amico A; Carta M; D'Ursi AM; Bertini E; Pellizzoni L; Usiello A
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges.
    Bayoumy S; Verberk IMW; Vermunt L; Willemse E; den Dulk B; van der Ploeg AT; Pajkrt D; Nitz E; van den Hout JMP; van der Post J; Wolf NI; Beerepoot S; Groen EJN; Tüngler V; Teunissen CE
    Clin Chem Lab Med; 2024 Jun; 62(7):1252-1265. PubMed ID: 38215341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nusinersen: First Global Approval.
    Hoy SM
    Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
    Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
    Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.
    Wurster CD; Günther R; Steinacker P; Dreyhaupt J; Wollinsky K; Uzelac Z; Witzel S; Kocak T; Winter B; Koch JC; Lingor P; Petri S; Ludolph AC; Hermann A; Otto M
    Ther Adv Neurol Disord; 2019; 12():1756286419846058. PubMed ID: 31205491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy.
    Ando S; Osanai D; Takahashi K; Nakamura S; Shimazawa M; Hara H
    J Pharmacol Sci; 2020 Dec; 144(4):204-211. PubMed ID: 33070839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
    MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
    CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Scientific rationale for a higher dose of nusinersen.
    Finkel RS; Ryan MM; Pascual Pascual SI; Day JW; Mercuri E; De Vivo DC; Foster R; Montes J; Gurgel-Giannetti J; MacCannell D; Berger Z
    Ann Clin Transl Neurol; 2022 Jun; 9(6):819-829. PubMed ID: 35567345
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-Based Therapy for Spinal Muscular Atrophy.
    Han F; Ebrahimi-Barough S; Abolghasemi R; Ai J; Liu Y
    Adv Exp Med Biol; 2020; 1266():117-125. PubMed ID: 33105498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
    Abreu NJ; Waldrop MA
    Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples.
    Welby E; Rehborg RJ; Harmelink M; Ebert AD
    Hum Mol Genet; 2022 Jun; 31(11):1830-1843. PubMed ID: 34919695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Motor unit number index (MUNIX) in children and adults with 5q-spinal muscular atrophy: Variability and clinical correlations.
    Mendonça RH; Machado LMS; Heise CO; Polido GJ; Matsui C; Silva AMS; Reed UC; Zanoteli E
    Neuromuscul Disord; 2021 Jun; 31(6):498-504. PubMed ID: 33824074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.